Tag Archives: Mekinist®

Novartis announces EC approval for Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for adjuvant treatment of BRAF V600 mutation-positive melanoma

Posted on 31, August 2018 by

Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients   More than 50% of stage III melanoma patients are likely to recur to stage IV during their lifetime … Read the full press release →

Posted in European Union, Healthcare, Pharma & Biotech, Switzerland

Tagged , , , , , , , ,

Novartis: updated data from study shows significant overall survival benefit for patients with aggressive form of melanoma when treated with Tafinlar® + Mekinist®

Posted on 29, September 2015 by

Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated significant improvement in health-related quality of life vs vemurafenib monotherapy in this … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , ,